Abstract We analysed 721 patients with primary malignant bone tumours treated in a single institution with regard to diagnosis, treatment and prognosis. From 1965From to 1974 patients were treated, of whom 17% had no surgery, 36% underwent resection and 46% underwent amputation. Margins of resection were intralesional in 21%, 72% of patients received chemotherapy and overall survival rate was 24%. From 1975 to 1984, 174 patients were treated, of whom 12% had no surgery, 54% underwent limb salvage procedures and 34% underwent amputation or resection-replantation. Margins of resection were intralesional in 16% 67% of patients received chemotherapy and overall survival rate was 46%. From 1985 to 1994, 393 patients were treated, of whom 7% had no surgery, 77% underwent limb salvage procedures -mainly with endoprostheses -and 15% underwent amputation or resection-replantation. Margins of resection were intralesional in 12%, 68% of patients received chemotherapy and overall survival rate was 62%. Advancements in the treatment of primary malignant bone tumours justify limb salvage procedures in combination with highly effective polychemotherapy in specialised centres and has resulted in an overall survival rate of more than 60%.
Introduction
Between January 1, 1965 and December 31, 1994, 1,716 patients with primary tumours and tumour-like lesions of the bone were registered in the Vienna Registry for Bone and Soft Tissue Tumors [17] . Of these patients, 721 had a primary malignant bone tumour. All registered patients, including those who had received no treatment due to either late referral, refusal to undergo therapy or death under treatment were included in the study.
The tumour registry continuously monitors and follows the patients. When a patient does not appear for their regular annual appointment the Bureau of Vital This study was conducted in conjunction with the Vienna Registry for Bone and Soft Tissue Tumors (Head: Prof. Dr. M. Dominkus), founded in 1964 as the Vienna Bone Tumor Registry Statistics in Austria is contacted. If the patient has died, the date of death is reported. This procedure makes it possible to give conclusive statements on prognosis and treatment of different tumour types. In keeping with highly malignant tumours the prognostic risk period for bone tumours is 3 years. We therefore consider we are justified in making prognostic statements on patients treated at our institution with a minimum of 3 years follow-up.
Patients and methods
In order to compare various treatment modalities as to prognosis and survival, we subdivided the whole period into three sections: (1) Period 1 (January 1965-December 1974), i.e. prior to the introduction of effective multidrug regimens. Surgical treatment mainly consisted of amputation (Fig. 1a-c) . (2) Period 2 (January 1975-December 1984), the period of effective multi-drug chemotherapy [6, 8, 14, 15, 16, 25] . Surgical treatment consisted of amputation and resection-replantation [11, 23] (Fig. 2a-d ) and limb salvaging procedures in selected cases combined with implantation of endoprostheses [9] . (3) Period 3 (January 1984-December 1994), the period marked by the application of highly effective chemotherapy protocols [7, 24] . Surgical treatment was mainly resection of the tumour and reconstruction using endoprostheses [10] (Fig. 3a-d) .
The histological diagnoses were similarly distributed within the three periods, with 45-50% osteosarcoma, 15-20% Ewing's sarcoma and primitive neuroectodermal tumours (PNET) and 12-17% chondrosarcomas. The comparable numbers of patients receiving chemotherapy in the three periods, independent of the success of treatment, is due to the nearly equal percentage of patients suffering from highly malignant bone tumours.
Radiotherapy was not analysed since, on the one hand, the application of this modality did not change over the years and, on the other hand, radiation therapy was not a major factor influencing the prognosis of primary Ewing's sarcoma of bone [7] .
Survival analysis was computed according to Kaplan-Meier, and statistical significances were determined with the log-rank test. If the log-rank test showed a significant difference between the three periods, the latter were compared in pairs in a second step. By this procedure the multiple level α is controlled.
Results
Between January 1965 and December 1974, 72% of the patients (111/154) underwent ineffective chemotherapyin most cases with single substances. Analysis of surgical treatment revealed a large number of intralesional resections (33=21.4%) and no operations (27=17.5%), amounting to a total of 38.9%. Most patients underwent transmedullary amputation (Table 1) . Of 154 patients, only 37 (24%) survived.
Between January 1975 and December 1984, effective chemotherapy protocols [14, 15, 16, 24, 25] were used and the survival rate increased to 46% (80/174); 67.2% of patients (117/174) underwent multidrug chemotherapy ( Table 2 ). The number of limb salvaging procedures (implantation of endoprostheses n=46, resections n=20) Between January 1985 and December 1994, primarily, the successful COSS 86 protocol [4] was applied in patients with osteosarcoma, while the CESS 86 and CESS 91 protocols [13] were used in those suffering from Ewing's sarcoma with a satisfactory outcome. Survival rate for osteosarcoma was 72% [4] and for Ewing's sarcoma 60% [7] ; 266 patients (67.7%) received chemotherapy while 127 (32.3%) with low-grade tumours (e.g. chondrosarcoma, parosteal osteosarcoma, etc.) did not. Surgical method of choice was resection. Endoprostheses were implanted in 196 patients. Children were provided with extendable prostheses [18] while patients with pelvic tumours were given pelvic prostheses [22] . One hundred nine patients underwent biological reconstruction (Table 3) . Percentage of amputations (n=36) and resection-replantations (n=24) [11, 23] was reduced to 15.3%. In most cases intralesional resection margins could be avoided. They were observed mainly in resections without implantation of an endoprosthesis, in tumours of the pelvic region and spine (47/109) ( Table 4) , and were seen in 50 patients (12.7%). Of 393 patients, 242 (61.6%) survived ( Table 3) .
The main reason for improvement in the second and third periods -reflected in a significant improvement in survival rate, especially among patients with osteosarcoma [4, 5, 24] and Ewing's sarcoma [7, 13] -was the introduction of effective neo-adjuvant multidrug chemotherapy (Fig. 4) . No improvement was achieved in patients who received no chemotherapy, as is reflected by the results for chondrosarcoma (Fig. 5) .
Discussion
Our tumour registry shows that the therapeutic strategy used for bone tumours has been changing over the last 3 decades. As a result, the survival rate of patients with primary malignant bone tumours is steadily increasing. The prevailing opinion as to the necessity of chemotherapy in high-grade lesions was not substantially different in the three periods. However, a significantly wider range of effective chemotherapy regimens was available in the second and third periods in contrast 201 to the first. In the third period, surgical margins were determined according to Enneking [2] in all but eight cases and revealed a high percentage of wide and radical margins, especially in the largest group, which was subjected to resection and replacement with endoprostheses. Resections without endoprosthetic replacement were mainly performed in the spine and pelvic region, as well as in cases with extensive soft-tissue involvement. Only these cases showed less optimal margins. Nevertheless, the overall results, indicating a survival rate of 61.6%, clearly justify the use of this procedure in specialised centres. The critical argument of repeated revisions being required in patients provided with endoprostheses [1] is counterbalanced by the fact that the functional outcome in these patients is good and the quality of life remains high, even after several revisions [3] . One problem during the first two periods was the high rate of intralesional resections within the pelvis and the spinal region when en bloc resection without implantation of a prosthesis was used. This feature has been improved by advancements in surgical technique [12, 22] , as reflected by 47 intralesional resections only in the third period. In certain subgroups, such as osteosarcomas in children and adolescents [19] or Ewing's sarcoma [20, 21] , results were considerably better than the overall outcome. A truly comparable parameter for progress in bone tumour therapy is death within 3 years. Death within 3 years was reduced to 55.2% in the first period, to 39.1% in the second and, finally, to 27.7% in the third, which were significant differences (Tables 1, 2 ) and 3.
In the treatment of malignant bone tumours the turning point in terms of better survival was achieved in 1975 when effective multidrug chemotherapy was introduced. A further turning point with regard to limb salvage and maintenance of body integrity was the introduction of technically improved endoprostheses in 1985. Although these results justify the transition from amputation to limb salvaging procedures at our institution, amputation may still be a life-saving and indispensable measure.
